Lord, Abbett & Co. LLC Travere Therapeutics, Inc. Transaction History
Lord, Abbett & Co. LLC
- $33.6 Billion
- Q3 2025
A detailed history of Lord, Abbett & Co. LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 135,919 shares of TVTX stock, worth $4.69 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
135,919
Previous 309,230
56.05%
Holding current value
$4.69 Million
Previous $4.58 Million
29.04%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding TVTX
# of Institutions
276Shares Held
101MCall Options Held
2.36MPut Options Held
955K-
Janus Henderson Group PLC London, X010.6MShares$366 Million0.12% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$264 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.72MShares$232 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.61MShares$228 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.98MShares$172 Million0.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $2.21B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...